HUP0400038A3 - Combination comprising n-{5-[4-{-methyl-piperazino-methyl)-benzoylamino]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent - Google Patents

Combination comprising n-{5-[4-{-methyl-piperazino-methyl)-benzoylamino]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent

Info

Publication number
HUP0400038A3
HUP0400038A3 HU0400038A HUP0400038A HUP0400038A3 HU P0400038 A3 HUP0400038 A3 HU P0400038A3 HU 0400038 A HU0400038 A HU 0400038A HU P0400038 A HUP0400038 A HU P0400038A HU P0400038 A3 HUP0400038 A3 HU P0400038A3
Authority
HU
Hungary
Prior art keywords
methyl
piperazino
benzoylamino
methylphenyl
pyridyl
Prior art date
Application number
HU0400038A
Other languages
Hungarian (hu)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0400038A2 publication Critical patent/HUP0400038A2/en
Publication of HUP0400038A3 publication Critical patent/HUP0400038A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
HU0400038A 2001-05-16 2002-05-15 Combination comprising n-{5-[4-{-methyl-piperazino-methyl)-benzoylamino]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent HUP0400038A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29142701P 2001-05-16 2001-05-16
PCT/EP2002/005362 WO2002092091A1 (en) 2001-05-16 2002-05-15 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent

Publications (2)

Publication Number Publication Date
HUP0400038A2 HUP0400038A2 (en) 2004-04-28
HUP0400038A3 true HUP0400038A3 (en) 2007-05-29

Family

ID=23120246

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400038A HUP0400038A3 (en) 2001-05-16 2002-05-15 Combination comprising n-{5-[4-{-methyl-piperazino-methyl)-benzoylamino]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent

Country Status (28)

Country Link
US (3) US20040167134A1 (en)
EP (2) EP1392313B1 (en)
JP (2) JP4477303B2 (en)
KR (2) KR20030094415A (en)
CN (1) CN1700917B (en)
AT (1) ATE359790T1 (en)
AU (1) AU2002342335B2 (en)
BR (1) BR0209647A (en)
CA (1) CA2444867C (en)
CO (1) CO5540315A2 (en)
CZ (1) CZ299756B6 (en)
DE (1) DE60219617T2 (en)
DK (1) DK1392313T3 (en)
EC (1) ECSP034823A (en)
ES (1) ES2283570T3 (en)
HK (1) HK1062895A1 (en)
HU (1) HUP0400038A3 (en)
IL (1) IL158274A0 (en)
MX (1) MXPA03010401A (en)
NO (2) NO325453B1 (en)
NZ (1) NZ529145A (en)
PL (2) PL392652A1 (en)
PT (1) PT1392313E (en)
RU (1) RU2318517C2 (en)
SI (1) SI1392313T1 (en)
SK (1) SK14042003A3 (en)
WO (1) WO2002092091A1 (en)
ZA (1) ZA200307665B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60134679D1 (en) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Nitrogen-containing aromatic heterocycles
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
AU2007201056B2 (en) * 2002-01-28 2010-06-10 Hyks-Instituutti Oy Treatment of rheumatoid arthritis using imatinib
GB0202874D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0311971D0 (en) * 2003-05-23 2003-06-25 Novartis Ag Organic compounds
JP4303726B2 (en) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 Urea derivative and method for producing the same
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
JP5066446B2 (en) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for predicting the effects of angiogenesis inhibitors
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Method for assay on the effect of vascularization inhibitor
BRPI0614090A2 (en) * 2005-08-03 2011-03-09 Novartis Ag use of hdac inhibitors for the treatment of myeloma
WO2007056118A1 (en) * 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CN101316590B (en) * 2005-11-07 2011-08-03 卫材R&D管理有限公司 Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
ES2556173T3 (en) 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
CN1899616A (en) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 New use of non-receptor tyrosine kinase c-Ab1 specific inhibitor
US8865737B2 (en) * 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CN101848895B (en) * 2007-11-09 2013-10-23 卫材R&D管理有限公司 Combination of anti-angiogenic substance and anti-tumor platinum complex
AU2009210098B2 (en) * 2008-01-29 2013-06-13 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
EP2915532B1 (en) * 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012144463A1 (en) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20150098605A (en) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous form of quinoline derivative, and method for producing same
KR102204279B1 (en) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
RS63559B1 (en) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd High-purity quinoline derivative and method for manufacturing same
PL3263106T3 (en) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (en) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd ANTI-CANCER AGENT

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
IL84497A (en) 1986-11-21 1994-10-21 Ciba Geigy Ag 2-(Imidazol-1-yl) ethane-1,1-diphosphonic acid derivatives, their preparation and pharmaceutical compositions containing them
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK1167384T3 (en) 1992-10-28 2007-04-10 Genentech Inc Vascular endothelial cell growth factor antagonists
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
JP4146514B2 (en) 1995-07-06 2008-09-10 ノバルティス アクチエンゲゼルシャフト Pyrrolopyrimidines and process for producing the same
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
SI0892789T2 (en) 1996-04-12 2010-03-31 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
AU2557097A (en) * 1996-04-17 1997-11-07 Board Of Regents, The University Of Texas System Enhanced expression of transgenes
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
DE19638745C2 (en) 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US20010051628A1 (en) * 1998-05-04 2001-12-13 H.-J. Su Huang Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors
JP4516690B2 (en) 1998-08-11 2010-08-04 ノバルティス アーゲー Isoquinoline derivatives having angiogenesis inhibitory activity
UA71587C2 (en) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
JP4731016B2 (en) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド Vascular endothelial growth factor antagonists and their uses
US6833373B1 (en) * 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
ES2265929T3 (en) 1999-03-30 2007-03-01 Novartis Ag FTALAZINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES.
GB9907908D0 (en) * 1999-04-07 1999-06-02 Bataille Regis Organic compounds
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
BR0014001A (en) * 1999-09-15 2002-05-21 American Home Prod Chemotherapy potentiation method and treatment of solid tumors
AU775373B2 (en) * 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2003512353A (en) * 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド Tyrosine kinase inhibitor
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7238525B2 (en) * 2000-06-30 2007-07-03 The Regents Of The University Of California Strategy for leukemia therapy
WO2002028409A2 (en) * 2000-10-05 2002-04-11 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
BR0114655A (en) * 2000-10-06 2004-02-10 Biomedicines Inc Method for identifying a combination of drugs for breast cancer treatment in an animal, Method for identifying a combination of breast cancer drugs in an animal, Method for identifying a combination of drugs for breast cancer prevention in an animal predisposed to said cancer, method for preventing breast cancer in an animal predisposed to said cancer, method for optimizing treatment of a breast cancer patient, method for optimizing a cancer prevention regimen in an animal, set useful for treating breast cancer in a patient in need of pharmaceutical composition and treatment for treating or preventing breast cancer
PL209733B1 (en) * 2000-10-27 2011-10-31 Novartis Ag Treatment of gastrointestinal stromal tumors
JP4499359B2 (en) * 2001-02-27 2010-07-07 ノバルティス アーゲー Combination comprising a signal conversion inhibitor and an epothilone derivative
JP4942297B2 (en) * 2002-10-25 2012-05-30 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド N- {5- [4- (4-Methylpiperazinomethyl) -benzoylamide] -2-methylphenyl} -4- (3-pyridyl) -2-pyridin-amine for the treatment of pulmonary hypertension Use of
US8168621B2 (en) * 2005-09-30 2012-05-01 Endece, Llc 6-substituted estradiol derivatives and methods of use
TW200740776A (en) * 2006-02-06 2007-11-01 Osi Pharm Inc N-phenylbenzotriazolyl c-kit inhibitors
WO2009140554A1 (en) * 2008-05-15 2009-11-19 University Of Southern California Ercc-1 expression predicts chemotherapy outcome

Also Published As

Publication number Publication date
CZ20033098A3 (en) 2004-02-18
ES2283570T3 (en) 2007-11-01
PT1392313E (en) 2007-07-17
RU2003135786A (en) 2005-02-27
CA2444867C (en) 2010-08-17
DK1392313T3 (en) 2007-06-25
MXPA03010401A (en) 2004-03-09
SI1392313T1 (en) 2007-08-31
JP4477303B2 (en) 2010-06-09
US20040167134A1 (en) 2004-08-26
CN1700917B (en) 2010-04-28
US20090202541A1 (en) 2009-08-13
PL392652A1 (en) 2010-12-06
KR20080091866A (en) 2008-10-14
NO20034713L (en) 2003-10-21
BR0209647A (en) 2004-07-27
SK14042003A3 (en) 2004-05-04
PL368068A1 (en) 2005-03-21
ATE359790T1 (en) 2007-05-15
CN1700917A (en) 2005-11-23
NO20076323L (en) 2007-12-07
ECSP034823A (en) 2003-12-24
ZA200307665B (en) 2004-04-21
KR20030094415A (en) 2003-12-11
AU2002342335B2 (en) 2006-02-02
CZ299756B6 (en) 2008-11-12
HUP0400038A2 (en) 2004-04-28
DE60219617D1 (en) 2007-05-31
CO5540315A2 (en) 2005-07-29
EP1392313A1 (en) 2004-03-03
IL158274A0 (en) 2004-05-12
NO20034713D0 (en) 2003-10-21
HK1062895A1 (en) 2004-12-03
US20120283206A1 (en) 2012-11-08
NZ529145A (en) 2005-07-29
CA2444867A1 (en) 2002-11-21
WO2002092091A1 (en) 2002-11-21
NO325453B1 (en) 2008-05-05
RU2318517C2 (en) 2008-03-10
JP2010059202A (en) 2010-03-18
JP2004531549A (en) 2004-10-14
EP2253319A1 (en) 2010-11-24
EP1392313B1 (en) 2007-04-18
DE60219617T2 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
HUP0400038A3 (en) Combination comprising n-{5-[4-{-methyl-piperazino-methyl)-benzoylamino]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
AU4560001A (en) Chemically resistant polythioethers and formation thereof
PL366545A1 (en) Herbicidal agent comprising benzoylcyclohexanediones and safeners
HK1059085A1 (en) Salts of a isothiazole-4-carboxamide and their useas anti-hyperproliferation agents
IL162107A0 (en) Herbicidal agents comprising benzoylpyrazoles and safeners
GB0114014D0 (en) Compostion and use
IL159538A0 (en) 8/17 heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors
HK1069385A1 (en) Heterocyclic compound and medicinal use thereof
EP1368051A4 (en) Urocortin-iii and uses thereof
IL151589A0 (en) New combination of a betablocker and a cholestrol-lowering agent
HUP0400165A3 (en) Herbicidal agents containing benzoylpyrazoles and safeners
HUP0301024A3 (en) Synergystic fungicidal compositions and use thereof
EP1391419A4 (en) Gripper and method of manufacturing the gripper
GB0224009D0 (en) Multilayer material and manufacturing method of the same
MXPA01002216A (en) Herbicidal benzoyloxy carboxylates and carboxamides.
HK1063486A1 (en) Novel expression vectors and uses thereof
EP1429747A4 (en) Core formulation comprising pioglitazone hydrochloride and a biguanide
IL156502A0 (en) Fungicidal mixtures from benzophenones and n-biphenyl nicotinamides
GB0224848D0 (en) Packaging and packaging material
EP1367123A4 (en) Neurotonin and use thereof
SG104988A1 (en) Leadframe and component with a leadframe
GB0122938D0 (en) Loading and unloading a weighscale
EP1466260A4 (en) Structure and operating principles of a device avatar
EP1429740A4 (en) Core formulation comprising troglitazone and a biguanide
HU0700787D0 (en) Combination comprising n{5-[-{methyl-piperazino-methyl)-benzoylamino]-2-methyphenyl}-4-3-pyridyl-2-pyrimidine-amine and a chemotherapeutic agent

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished